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Circulating dipeptidyl peptidase IV (DPPIV) activity is associated with worse
cardiovascular outcomes in humans and experimental heart failure (HF) models,
suggesting that DPPIV may play a role in the pathophysiology of this syndrome. Renal
dysfunction is one of the key features of HF, but it remains to be determined whether
DPPIV inhibitors are capable of improving cardiorenal function after the onset of HF.
Therefore, the present study aimed to test the hypothesis that DPPIV inhibition by
vildagliptin improves renal water and salt handling and exerts anti-proteinuric effects
in rats with established HF. To this end, male Wistar rats were subjected to left
ventricle (LV) radiofrequency ablation or sham operation. Six weeks after surgery,
radiofrequency-ablated rats who developed HF were randomly divided into two groups
and treated for 4 weeks with vildagliptin (120 mg/kg/day) or vehicle by oral gavage.
Echocardiography was performed before (pretreatment) and at the end of treatment
(post-treatment) to evaluate cardiac function. The fractional area change (FAC) increased
(34± 5 vs. 45± 3%, p< 0.05), and the isovolumic relaxation time decreased (33± 2 vs.
27± 1 ms; p< 0.05) in HF rats treated with vildagliptin (post-treatment vs. pretreatment).
On the other hand, cardiac dysfunction deteriorated further in vehicle-treated HF rats.
Renal function was impaired in vehicle-treated HF rats as evidenced by fluid retention,
low glomerular filtration rate (GFR) and high levels of urinary protein excretion. Vildagliptin
treatment restored urinary flow, GFR, urinary sodium and urinary protein excretion to
sham levels. Restoration of renal function in HF rats by DPPIV inhibition was associated
with increased active glucagon-like peptide-1 (GLP-1) serum concentration, reduced
DPPIV activity and increased activity of protein kinase A in the renal cortex. Furthermore,
the anti-proteinuric effect of vildagliptin treatment in rats with established HF was
associated with upregulation of the apical proximal tubule endocytic receptor megalin
and of the podocyte main slit diaphragm proteins nephrin and podocin. Collectively, these
findings demonstrate that DPPIV inhibition exerts renoprotective effects and ameliorates
cardiorenal function in rats with established HF. Long-term studies with DPPIV inhibitors
are needed to ascertain whether these effects ultimately translate into improved clinical
outcomes.
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INTRODUCTION
Dipeptidyl peptidase IV (DPPIV) is a widely expressed
ectopeptidase that exists anchored as a transmembrane protein or
in a soluble form in plasma and other body fluids (Lambeir et al.,
2003). The kidney is themain source of DPPIV, where the enzyme
is highly concentrated in the apical microvilli of the proximal
tubule cells (Kenny et al., 1976; Girardi et al., 2001). DPPIV
catalyzes the release of N-terminal dipeptides from polypeptides
with proline or alanine in the second position. Among the many
bioactive peptides cleaved by DPPIV, there is the gut hormone
glucagon-like peptide-1 (GLP-1), which is the major incretin
responsible for post-prandial insulin secretion. Indeed, DPPIV
inhibitors, commonly called gliptins, increase the bioavailability
of GLP-1 and improve systemic glucose homeostasis,
thereby constituting the second line oral therapy in type 2
diabetes.
In addition to their effects on glycemic control, DPPIV
inhibitors have been shown to produce cardioprotective and
renoprotective effects. These beneficial actions may also be
attributed, at least partially, to increased GLP-1 bioavailability.
Upon binding of GLP-1 to its receptor (GLP-1R) in the heart,
it induces activation of the cytoprotective signaling pathways
cAMP/PKA and PI3K/Akt (Ussher and Drucker, 2012), reduces
apoptosis (Ravassa et al., 2011), increases heart glucose uptake
(Bao et al., 2011), reduces infarct size (Timmers et al., 2009)
and improves coronary blood flow by means of its vasodilating
actions (Ban et al., 2008). Moreover, GLP-1 induces diuresis
and natriuresis by increasing renal blood flow and glomerular
filtration rate (GFR) and by reducing NHE3-mediated sodium
reabsorption in the renal proximal tubule sodium via cAMP/PKA
activation (Crajoinas et al., 2011; Rieg et al., 2012; Farah et al.,
2016).
Recent translational studies have suggested that increased
DPPIV activity may play an important role in the
pathophysiology of heart failure (HF) (Shigeta et al., 2012;
dos Santos et al., 2013; de Almeida Salles et al., 2016). We
have previously showed that increased circulating DPPIV
activity is associated with worse cardiovascular outcomes
in human and experimental HF and that long-term DPPIV
inhibition exerts cardioprotective actions that prevent the
development/progression of HF in rats (dos Santos et al., 2013;
de Almeida Salles et al., 2016).
Worsening renal function in the setting of HF is widely
accepted as an independent risk factor for a poor prognosis. HF is
often associated with sodium and water retention, a reduction in
renal blood flow and GFR (Laskar and Dries, 2003), renal tubular
damage and proteinuria (Udani and Koyner, 2010; Boerrigter
et al., 2013). Despite its natriuretic actions, DPPIV inhibitors
have also been shown to confer renoprotection by reducing
urinary protein excretion and ameliorating renal damage in a
variety of clinical and experimental studies in diabetic, obese
and renal failure patients and rodents (Hattori, 2011; Kanasaki
et al., 2014; Scirica et al., 2014; Sharkovska et al., 2014; Nakamura
et al., 2016; Tsuprykov et al., 2016). However, it remains to be
established whether DPPIV inhibitors are capable of reversing
cardiorenal dysfunction after the onset of HF.
Given the inextricable importance of heart-kidney
interactions in HF, the main purpose of the present study
was to test the hypothesis that DPPIV inhibition by vildagliptin
improves renal water and salt handling and exerts anti-
proteinuric effects in rats with established HF. The molecular
mechanisms underlying these renoprotective effects were also
investigated.
MATERIALS AND METHODS
Reagents and Antibodies
The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was
a gift from Novartis Pharmaceuticals (Basel, Switzerland). The
monoclonal antibody (mAb) against the Na+/H+ exchanger
isoform 3 (NHE3), clone 3H3 (Kocinsky et al., 2005), and a
polyclonal antibody against megalin were kindly provided by
Dr. Peter Aronson and Dr. Daniel Biemesderfer, respectively
(Yale University, New Haven, CT). A mAb antibody against
DPPIV (clone 5H8), a mouse mAb, clone 14D5, that recognizes
NHE3 only when it is phosphorylated at serine 552 (Kocinsky
et al., 2005) and polyclonal antibodies against the glucagon-like
peptide-1 receptor (GLP-1R), cubilin, nephrin, and podocin were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The
polyclonal antibody against phospho-(Ser/Thr) protein kinase
A (PKA) substrates (Gronborg et al., 2002) was obtained from
Cell Signaling (Beverly, MA). The mAb against actin (JLA20)
was purchased from Merck Millipore (Darmstadt, Germany).
A polyclonal antibody against CD31 was purchased from
Abcam (Cambridge, MA). Horseradish peroxidase-conjugated
goat anti-mouse, goat anti-rabbit and rabbit anti-goat secondary
antibodies were purchased from Jackson ImmunoResearch (West
Grove, PA). Chemicals were obtained from Sigma-Aldrich
(St. Louis, MO) unless otherwise specified.
Animal Model
Experiments were carried out using male Wistar rats (2–3
months old, 200–250 g) obtained from the University of São
Paulo Medical School, São Paulo, SP, Brazil. Animals were
maintained in the Heart Institute animal facility in compliance
with the Ethical Principles of the Brazilian College of Animal
Experimentation and were approved by the Institutional Animal
Care and Use Committee.
Experimental HF was induced by left ventricular (LV)
myocardial injury after radiofrequency catheter ablation as
previously described (Antonio et al., 2009; Inoue et al., 2012;
dos Santos et al., 2013; de Almeida Salles et al., 2016).
Briefly, rats were anesthetized with isoflurane, intubated and
mechanically ventilated with oxygen enriched air and kept
warm during surgical procedures (37◦C). Subsequently, a left-
side thoracotomy was performed at the fourth intercostal
space. LV injury was created by delivering high-frequency
currents (1000 KHz, 12w, during 10 s) generated by a
conventional radiofrequency generator (model TEB RF10;
Tecnologia Eletrônica Brasileira, São Paulo, Brazil). The sham
group underwent similar surgical procedures, but was not
subjected to radiofrequency myocardial ablation. Six weeks
after surgery, radiofrequency-ablated rats that developed HF
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were randomly divided into two groups and treated during
4 weeks with vildagliptin (120 mg/kg/day bid) or vehicle by
oral gavage. Vehicle-treated sham rats were used as controls.
Echocardiographic evaluation of left ventricle systolic and
diastolic function as well as serum levels of BNP were used
to characterize HF. HF was considered when the fractional
area change (FAC) was lower than 40% and circulating levels
of brain natriuretic peptide (BNP) were higher than 1.0
ng/mL. For determination of BNP serum concentration, blood
samples were withdrawn from the rat retro-orbital sinus under
isoflurane anesthesia and immediately transferred into chilled
tubes containing clot activator and gel for serum separation (BD
vacutainer R© SST R© II Advance R©). Serum levels of BNP were
measured by enzyme-linked immunoassay (ELISA) (BNP 32 Rat
ELISA kit, Abcam) according to the manufacturer’s instructions.
Mortality rate between HF rats treated with vehicle or with
vildagliptin was lower than 5% and did not differ between these
two groups of rats.
Echocardiography
Doppler echocardiography was performed 6 weeks after
LV-radiofrequency ablation or sham surgery (pretreatment) and
after treatment with vehicle or vildagliptin (post-treatment).
Animals were anesthetized with ketamine and xylazine (50
mg/kg and 10 mg/kg, respectively, i.p.) and placed in the left
lateral decubitus position (45◦ angle) to obtain cardiac images.
Images were captured and analyzed using Sonos 5500 ultrasound
equipment (Philips Medical System, Bothell, WA) with a 12–14
MHz transducer (2 cm depth with fundamental and harmonic
imaging). Echocardiographic images were acquired placing the
cursor of pulsed wave Doppler in the LV outflow tract to
display the end of aortic ejection and the onset of mitral inflow.
End-diastolic (DA) and end-systolic (SA) transverse areas of LV
were measured in parasternal-papillary short-axis images. FAC
was calculated based on the areas using the following equation:
FAC (in %) = (DA − SA)/DA × 100. Diastolic function was
obtained at apical plane images. Isovolumetric relaxation time
(IVRT) was measured in tissue Doppler images in the lateral wall
of the ventricle. Transthoracic echocardiography was performed
by two investigators who were blind to the experimental groups.
Renal Function
Renal function was evaluated as described previously (Inoue
et al., 2013). In brief, rats were housed individually in metabolic
cages (Tecniplast, Buguggiate, VA, Italy) for four consecutive
days. The first day was used to adapt the rats to the cages,
and the following 3 days were used to assess renal function.
Food consumption and water intake were monitored daily.
Urine samples collected during each 24-h period were used
to determine urine output, creatinine, sodium and protein
excretion. At the end of the experiment, terminal arterial
blood samples were collected from the abdominal aorta and
transferred into vacutainer tubes (BD vacutainer R© SST R© II
Advance R©, Franklin Lakes, NJ) to obtain serum. Serum was
separated by centrifugation at 4000 rpm for 15 min for the
measurement of biochemical parameters. Urine output was
measured gravimetrically. Creatinine clearance was used to
estimate GFR. Creatinine concentration was measured by the
kinetic alkaline picrate (Jaffe) reaction (LabTest, Lagoa Santa,
MG, Brazil). Serum and urine sodium concentrations were
measured by electrolyte analyzer (ABL800 FLEX, Radiometer
Copenhagen). Total urinary protein excretion was measured
using a commercially available kit based on the pyrogallol red-
molybdate method (Sensiprot, Labtest). All experiments were
performed following the manufacturer’s instructions.
Determination of Active GLP-1 Serum
Levels
For the quantitative determination of active GLP-1, blood
was collected and transferred to vacutainer collecting tubes
containing the DPPIV inhibitor P32/98 (10 µM) (Abcam).
Serum levels of active GLP-1 (7–36) were measured by ELISA
(Glucagon-Like Peptide-1 (Active) ELISA, Merck Millipore)
according to the manufacturer’s instructions.
Measurement of Blood Glucose
Sham and HF rats treated with vehicle or vildagliptin were fasted
for 8 h. The blood glucose level was determined from their tail vein
using the ACCU-CHECK R© Performa meter (Roche Diagnostics
GmbH, Mannheim, Germany).
Biometric and Morphometric Analysis
Anesthetized rats (ketamine and xylazine 50 mg/kg and 10
mg/kg, respectively, i.p.) were killed by decapitation, and their
hearts, kidneys and lungs were immediately removed and
weighed. The heart and kidney weight to body weight ratio were
used as an index of organ hypertrophy. The relative water content
of lung tissue was calculated using the following equation: Lung
water content (in %)= (lung wet weight− lung dry weight)/lung
wet weight× 100.
The apex of the heart of each rat was separated and
prepared for histological and immunohistochemical assays. The
remainder of the heart was frozen at −80◦C for molecular
analysis. Five-micro meter sections of paraffin-embedded tissue
were mounted onto slides and stained with hematoxylin and
eosin (for determination of nuclear cell volume) or picrosirius
red (for the determination of interstitial collagen density).
A computerized image acquisition system (Leica Imaging
Systems, Bannockburn, IL) was used for the analyses. As an
estimate of myocyte hypertrophy, the average nuclear volume
was determined in 70−90 cardiomyocytes cut longitudinally,
acquired in 5 randomized 400× magnification fields per each
animal, and calculated according to the following equation:
nuclear volume = pi × D × d2/6 (d = shorter nuclear diameter;
D = longer diameter) (Gerdes et al., 1994; dos Santos et al.,
2013). Interstitial fibrosis in the remodeled LV was evaluated as
the percent area occupied by collagen fibers, excluding stained
ablation scars and perivascular fibers. After digitalization, the
red-stained areas were quantified as the average percentage of
the total area from each of five randomized 200 × magnification
fields per animal. The observer was blinded to the experimental
groups. Sections from the midventricular level of each heart
(4 µm) stained with picrosirius red were scanned, and the
circumference of the fibrotic infarct area was measured with
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Image J software (NIH). The size of the injured myocardial area
was determined by calculating the percent of the length of the
area occupied by the scar at the midventricular section. In this
regard, we previously demonstrated that this single measure is
a satisfactory prediction of average infarct extension (dos Santos
et al., 2008).
Immunohistochemical staining was performed to measure
capillary density and to define the localization of DPPIV in the
heart. Endogenous peroxidase activity was blocked by 3 min
incubation in 3% H2O2 (seven times at room temperature)
and then rinsed with PBS (137 mM NaCl, 2.5 mM KCl, 10
mM Na2HPO4, and KH2PO4 176 mM, pH 7.4). Non-specific
reactions were blocked in 2% goat serum for 20 min and then
incubated with the primary antibodies. The primary antibodies
used were the mAb anti-DPPIV antibody or the rabbit polyclonal
anti-CD31 antibody, and both of them were diluted 1:50 in
the blocking buffer containing 5% BSA. Negative controls were
not incubated with primary antibodies. After 18 h incubation
at 4◦C, tissues were washed 3 times for 5 min with PBS
and incubated with secondary antibody. After washing in PBS,
tissue sections were incubated with an HRP solution Universal
LSAB 2 kit containing biotin-streptavidin complex for signal
amplification of the primary antibody. Immunoreactions were
detected with 3,3′-diaminobenzidine tetrahydrochloride (DAB)
for 7 min. Immunostaining was visualized under a microscope
and positive staining (brown color) analyzed under 400 ×
magnification. For capillary density evaluation, the number of
capillaries CD31+ was counted from 10 randomized fields
per animal at 400 × magnification. Image analysis software
(Leica Imaging Systems, Bannockburn, IL, USA) was used to
measure the capillary density, calculated as the number of
capillaries per tissue area in the remote LV wall. The measured
total tissue area was corrected for the remaining interstitial
space.
Determination of DPPIV Activity and
Abundance
DPPIV activity was assayed in rat serum, kidney and heart
homogenates using a colorimetric method that measures the
release of p-nitroaniline resulting from the hydrolysis of
glycylproline p-nitroanilide tosylate (Pacheco et al., 2011). Renal
and heart DPPIV activity was normalized to total protein levels,
and DPPIV abundance in the rat kidney and heart homogenates
were analyzed by immunoblotting.
Protein Extraction from Heart and Renal
Cortex
Harvested hearts from rats were homogenized in a Polymix PX-
SR 50 E homogenizer (Kinematica, AG, Switzerland) in ice-
cold phosphate buffered saline (PBS) (10 mmol/L phosphate,
140 mmol/L NaCl, pH 7.4), including phosphatase inhibitors
(15 mM NaF and 50 mM sodium pyrophosphate) and Halt
Protease Inhibitor Cocktail (Thermo Fisher Scientific, Rockford,
IL). Renal cortical homogenates were prepared as previously
described (Crajoinas et al., 2014).
Determination of Protein Kinase A (PKA)
Activity in Renal Cortical Homogenates
Equal amounts (25 µg) of renal cortical homogenates were
resolved by SDS-PAGE and analyzed by immunoblotting
using an antibody specific for phosphorylated PKA substrates
(Gronborg et al., 2002; Crajoinas et al., 2014).
SDS-Page and Immunoblotting
Equal protein amounts of heart, renal cortical homogenate or a
volume of urine containing 25 µg of creatinine were solubilized
in SDS sample buffer (2% SDS, 10% glycerol, 0.1% bromophenol
blue, 50 mmol/L Tris, pH 6.8), and subjected to 7.5 or 10%
SDS-PAGE polyacrylamide gel. The separated proteins were
transferred from the gel to a polyvinylidene difluoride membrane
(PVDF) (Immobilon-P, Merck Millipore, Darmstadt, Germany)
at 350 mA for 8–10 h at 4◦C with a TE 62 Transfer Cooled
Unit (GE HealthCare, Piscataway, NJ, USA), and stained with
Ponceau S. PVDF membranes containing transferred proteins
were subsequently blocked with 5% non-fat dry milk or 5%
bovine serum albumin and 0.1% Tween 20 in PBS at a pH
of 7.4 for 1 h to block non-specific binding of the antibody,
followed by overnight incubation in the primary antibody. The
membranes were then washed five times in blocking solution
and incubated for 1 h at room temperature with an appropriated
horseradish-peroxidase-conjugated immunoglobulin secondary
antibody (1:2000). After washing five times in blocking solution
and twice in PBS (pH 7.4), the protein bands were detected using
enhanced chemiluminescence system (GE Healthcare) according
to the manufacturer’s protocols. The visualized bands were
digitized using an ImageScanner (GEHealthCare) and quantified
using the Scion Image Software package (Scion Corporation,
Frederick, MD). Gels containing samples of urine were silver
stained using ProteoSilver Plus Kit.
Quantitative Real Time RT-PCR
Total RNA was isolated from hearts using Trizol (Thermo
Fisher Scientific, Carlsbad, CA) according to the manufacturer’s
instructions, quantified (ND-1000 spectrophotometer—
NanoDrop Technologies, Inc.), and treated with DNase-I.
First-strand cDNA synthesis was performed using Super-
Script III Reverse Transcriptase (Invitrogen) following
the manufacturer’s guidelines. The oligonucleotide
primers CCAACTCCAGAGGACAACCT (forward) and
TCTTCGTCCGTGTACCACAT (reverse) were used to detect
DPPIV, and GATTCTGCTCCTGCTTTTCC (forward) and
TCTTTTGTAGGGCCTTGGTC (reverse) were used to detect
BNP. PCR products were visualized on 0.8% agarose gels
with ethidium bromide. Reactions were carried using SYBR
Green PCR Master Mix-PE (Thermo Fisher Scientific) on an
ABI Prism R© 7500 Fast Sequence Detection System (Applied
Biosystem, Foster City, CA). The comparative threshold cycle
method was used for data analyses. All samples were assayed in
triplicate. Transcripts for three reference genes were determined:
beta-actin (forward: CGTTGACATCCGTAAAGACC; reverse
GCCACCAATCCACACAGA), GAPDH (forward: ATGGTGAA
GGTCGGTGTG; reverse: GAACTTGCCGTGGGTAGAG) and
cyclophilin A (forward: AATGCTGGACCAAACACAAA-30;
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reverse: CCTTCTTTCACCTTCCCAAA). The BestKeeper
software (Pfaffl et al., 2004) was used to identify the best suit
reference gene (Cyclophilin A) for data normalization under our
experimental conditions. Relative expression was analyzed by
the 2−11CT method.
Statistical Analysis
All values are expressed as the means ± standard error of the
mean (SEM). Comparisons between two groups were performed
using unpaired t-tests. If more than two groups were compared,
the statistical significance was determined using one-way analysis
of variance (ANOVA) followed by Tukey’s post-hoc test. The
results were considered statistically significant when p< 0.05.
RESULTS
DPPIV Inhibition Improves Cardiac
Function in Rats with Established HF
As seen in Table 1, treatment with the DPPIV inhibitor
vildagliptin reduced serum DPPIV activity by >70% in HF rats
compared to HF rats treated with the vehicle.
At the end of the 4-week treatment period (post-treatment),
cardiac dysfunction was aggravated in HF rats who received
the vehicle compared to the pretreatment period (Figure 1).
Worsening of cardiac dysfunction in these animals were
evidenced by a decline in FAC (37 ± 2 vs. 30 ± 2%, p < 0.05)
(Figure 1A), which reflects a progressive reduction in the overall
LV contractility, as well as an increase in IVRT (33.1 ± 0.7
vs. 36.5 ± 2.4 ms, p < 0.05) (Figure 1B), which reflects an
aggravated diastolic dysfunction. Additionally, vehicle-treated
HF rats displayed a remarkable increase in BNP serum levels
from pretreatment to post-treatment (0.94 ± 0.01 vs. 2.65 ±
0.46 ng/mL p < 0.001). Conversely, HF rats treated with the
DPPIV inhibitor vildagliptin exhibited an increase in FAC (34 ±
5 vs. 45 ± 3%, p < 0.05) (Figure 1A) and a reduction in
IVRT (33 ± 2 vs. 27 ± 1 ms, p < 0.05) (Figure 1B) and
in serum BNP 32 levels (0.93 ± 0.07 vs. 0.55 ± 0.02 ng/mL,
p < 0.001) (Figure 1C) compared with the pretreatment period.
As expected, cardiac function and serum BNP 32 levels were
similar between pretreatment and post-treatment periods in
sham rats.
DPPIV Inhibition Attenuates Cardiac
Remodeling and Increases Capillary
Density in Rats with Established HF
The biometric characteristics of the rats are shown in
Table 1. Average body weight gain was similar among the
three experimental groups. Vildagliptin administration did not
influence the size of the injured myocardial area. Vehicle-
treated HF rats showed higher heart weight-to-body weight
ratio, indexed lung mass and the percent of water content when
compared with sham-operated controls. In vildagliptin-treated
rats, the heart weight-to-body weight ratio was lower than in
vehicle treated HF rats but remained higher than in sham rats.
The relative water content of lung tissue in vildagliptin treated
HF rats was reduced to sham levels.
TABLE 1 | Biometric parameters and serum DPPIV activity in sham and HF
rats treated with vehicle (HF) or vildagliptin for 4 weeks.
Sham HF HF + IDPPIV
Initial body weight, g 252±10 235±8 248± 12
Final body weight, g 420±9 441±8 457± 9
Heart/BW, mg/g 2.55±0.02 3.01±0.08*** 2.72± 0.05##
Lung/BW, mg/g 3.05±0.07 3.56±0.17*** 3.03± 0.08###
Lung water content, % 78.9±0.12 80.2±0.2*** 78.8± 0.1###
Injured myocardial area, % − 42.1±1.6 40.5± 1.9
Kidney/BW, mg/g 6.00±0.21 6.16±0.24 6.09± 0.19
Serum DPPIV Activity, OD 0.373±0.02 0.659±0.03*** 0.186± 0.010***,###
Values are means ± SEM. BW, body weight; OD, optical density. ***p < 0.001 vs. Sham.
##p < 0.01 and ###p < 0.001 vs. HF.
FIGURE 1 | Treatment with vildagliptin improves cardiac function in rats with established HF. Doppler echocardiography and quantitative determination of
serum BNP were performed 6 weeks after LV-radiofrequency ablation or sham surgery (pretreatment) and after 4 weeks of treatment with vehicle or vildagliptin
(post-treatment). (A) Fractional area change (FAC). (B) Isovolumic relaxation time (IVRT). (C) Serum BNP 32 levels. Values are means ± SEM. #p < 0.05 and
###p < 0.001 vs. pretreatment.
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FIGURE 2 | DPPIV inhibition attenuates cardiac remodeling and capillary rarefaction in rats with established HF. (A) Myocardial hypertrophy was assessed
in HF rats treated with vehicle (HF) or vildagliptin (HF + IDPPIV) by measuring cardiomyocyte nuclear volumes in heart sections treated with stained with
hematoxylin-eosin (400×original magnification). (B) Cardiac interstitial fibrosis was evaluated in heart sections stained with picrosirius red (200×original magnification).
(C) Representative immunohistochemical staining of CD31 in sections of the LV viable wall showing individual capillaries (small dark circles) (400×original
magnification). n = 7–9 rats/group. Values are means ± SEM. **p < 0.01 and ***p < 0.001 vs. Sham. #p < 0.05 and ###p < 0.001 vs. HF.
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FIGURE 3 | Heart DPPIV activity and expression in sham and HF rats treated with the DPPIV inhibitor vildagliptin or with the vehicle. (A) Heart DPPIV
activity was measured in sham and HF rats treated with vehicle (HF) or vildagliptin (HF + IDPPIV) by colorimetry. (B) Representative immunohistochemical staining of
DPPIV in the heart (400×original magnification). (C) Graphical representation of the relative gene expression of DPPIV in the heart of sham and HF rats treated with
vildagliptin or with the vehicle. The levels of mRNA of DPPIV were measured by real-time PCR and cyclophilin used as an internal control. Values are means ± SEM.
**p < 0.01 and ***p < 0.001 vs. Sham. ###p < 0.001 vs. HF.
The potential anti-hypertrophic effects of DPPIV inhibition in
rats with established HF were further evaluated by histological
analysis of hematoxylin and eosin-stained cardiac sections
(Figure 2A). The results of these analyses demonstrated that
the mean cardiomyocyte nuclear volume in vehicle-treated HF
rats was larger than that of sham- and vildagliptin-treated
rats, which significantly attenuated this increase (Figure 2A).
In addition, vehicle-treated HF rats had a higher percentage of
interstitial collagen in the reminiscent myocardium than sham
rats, which was significantly attenuated by DPPIV inhibition
(Figure 2B). Representative photomicrographs of CD31 stained
sections in the LV viable wall showing individual capillaries are
presented in the Figure 2C. HF rats treated with vildagliptin
showed a slight but significant increase in the amount of CD31+
capillaries compared to the vehicle-treated group in the remote
area of injured hearts indicating a reduced capillary rarefaction.
Moreover, the non-treated HF rats had a significant decrease in
the number of capillaries per mm2 compared to sham group
(Figure 2C).
DPPIV Inhibition Suppresses Cardiac
DPPIV Activity and Expression in Rats with
Established HF
Vehicle-treated HF rats exhibited higher levels of cardiac
DPPIV activity compared to sham and vildagliptin, which
markedly decreased DPPIV activity (Figure 3A). Increased
heart DPPIV expression in HF rats was observed both
in cardiac endothelial cells as well as in the pericardium
membrane (Figure 3B). Notwithstanding, vildagliptin reduced
DPPIV expression at both sites. Higher DPPIV activity and
protein expression was accompanied by higher levels of DPPIV-
mRNA expression in the heart of HF rats compared to
sham rats, which was also attenuated by vildagliptin treatment
(Figure 3C).
DPPIV Inhibition Diminishes DPPIV Activity
but Not Expression in the Kidney of Rats
with Established HF
The activity and protein expression of DPPIV in the renal cortex
of sham and HF rats treated with vildagliptin or with the vehicle
are illustrated at the Figure 4. Renal cortical DPPIV activity was
lower in HF rats treated with vildagliptin compared to both sham
and vehicle-treated HF rats (Figure 4A). As shown in Figure 4B,
the expression of DPPIV in the renal cortex was similar among
the three groups of rats.
DPPIV Inhibition Increases Circulating
GLP-1 Active and Restores PKA Signaling
in the Kidneys of Rats with Established HF
The levels of active GLP-1 in HF rats treated with vildagliptin
(20.9 ± 2.9 pM) were approximately three times higher than
those of vehicle-treated HF rats (6.9 ± 0.4 pM p < 0.001) and
sham rats (8.2 ± 0.5 pM P < 0.001) (Figure 5A). However,
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FIGURE 4 | Renal DPPIV activity and expression in sham and HF rats treated with the DPPIV inhibitor vildagliptin or with the vehicle. (A) Renal DPPIV
activity was measured in sham and HF rats treated with vehicle (HF) or vildagliptin (HF + IDPPIV) by colorimetry. (B) Renal cortical DPPIV abundance was evaluated by
immunoblotting. Equal amounts of protein (10 µg for DPPIV and 5 µg for actin) were subjected to SDS-PAGE, transferred to a PVDF membrane and incubated with
the following primary antibodies: anti-DPPIV (1:1000) and anti-actin (1:50,000). Membranes were stained with Ponceau S prior to antibody incubation, and the Actin
was used as an internal control. Values are means ± SEM. ##p < 0.01 vs. HF.
despite the differences in GLP-1 levels between vehicle-treated-
HF and HF rats treated with vildaglitpin, the fasting blood glucose
levels were similar among the groups (Figure 5B).
The effect of DPPIV inhibition on renal cortical PKA activity,
a downstream effector for the GLP-1R (Farah et al., 2016), was
estimated by immunoblotting. As shown in Figure 5C, vehicle-
treated HF rats exhibited lower renal cortical PKA activity
than sham rats. Vildagliptin treatment increased the levels of
phosphorylated PKA substrates in the renal cortex of HF rats
compared to vehicle-treated HF rats.
DPPIV Inhibition Improves Renal Sodium
and Water Handling in Rats with
Established HF
The effects of DPPIV inhibition on sodium and water handling
are shown in Figure 7. HF rats exhibited lower urinary flow
(Figure 6A) and sodium excretion (Figure 6B) compared to
sham rats, whereas treatment with vildagliptin significantly
restored urine output and sodium excretion in rats with
established HF (Figures 6A,B). The mean values of water and
sodium intake were not significantly different among the three
experimental groups of rats (Figures 6C,D). Accordingly, HF
rats treated with the vehicle exhibited higher positive water
(Figure 6E) and sodium balance (Figure 6F) compared to sham
rats. Daily water and sodium balance in HF rats treated with
vildagliptin were similar to sham rats and lower than non-treated
HF rats.
DPPIV Inhibition Increases NHE3
Phosphorylation at Serine 552 in the Renal
Cortex of HF Rats
Lower levels of phosphorylated NHE3 at the PKA consensus
site serine 552 in the proximal tubule has been associated
with higher NHE3 transport activity (Crajoinas et al., 2010,
2014; Girardi and Di Sole, 2012; Pontes et al., 2015; Farah
et al., 2016). As show in Figures 7A,B, the levels of NHE3
phosphorylation at serine 552 (PS552-NHE3) were much lower
in HF than in sham-operated rats (39 ± 4 vs. 100 ± 3%,
P < 0.01) (Figures 7A,B). In rats treated with vildagliptin,
PS552-NHE3 was higher than in vehicle treated HF rats and
similar to sham rats. Total NHE3 protein expression was
slightly higher in the renal cortex of vehicle-treated HF rats
than in sham-operated rats and vildagliptin-treated HF rats
(Figures 7A,C).
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FIGURE 5 | DPPIV inhibition increases active GLP-1 serum concentration as well as renal cortical GLP-1R expression and PKA activation in HF rats.
(A) Serum levels of active GLP-1 were determined by ELISA in sham and HF rats treated with vildagliptin (HF + IDPPIV) or vehicle (HF). (B) Fasting glucose serum
levels in sham, HF rats and HF rats treated with vildagliptin. n = 11–17 rats/group (A,B). (C) Levels of phosphorylation of PKA substrates in the renal cortex of Sham,
HF and HF rats treated with vildagliptin (HF + IDPPIV) were evaluated by immunoblotting using an antibody that recognizes proteins containing a phospho-Ser/Thr.
Top: Equal amounts of protein (25 µg) from each rat were subjected to SDS-PAGE, transferred to a PVDF membrane and incubated with the antibody anti-pSer/Thr.
Actin was used as an internal control. Bottom: The sum total of all phospho-PKA proteins per lane was estimated by densitometry and normalized by actin. The
combined data from 6 experiments are represented as columns in a bar graph. Values are means ± SEM. ***p < 0.001 vs. Sham. ###p < 0.001 vs. HF.
DPPIV Inhibition Improves GFR and Exerts
Anti-Proteinuric Effects in Rats with
Established HF
As depicted in Figure 8, vehicle-treated HF rats exhibited a much
lower GFR (Figure 8A) and amuch higher excretion of protein in
the urine than sham rats (Figures 8B,C). Vildagliptin treatment
restored both GFR and proteinuria to sham levels. These changes
on GFR were not accompanied by changes on the kidney/body
weight ratios (Table 1). The profile of urinary proteins excreted
by HF and sham rats was evaluated by SDS-PAGE, and the
amount of intact albumin was semiquantitatively determined by
densitometry. As seen in Figures 8C,D, the urinary excretion of
intact albumin was remarkably higher in vehicle-treated HF rats
compared to both sham and HF rats treated with vildagliptin.
Moreover, the levels of albumin excretion were not significantly
different between vildagliptin-treated HF rats and sham rats.
Analysis of the pattern of proteinuria excreted by vehicle-treated
HF rats (Figure 8C) suggests a mixed origin of proteinuria
because both glomerular and tubular protein fractions, i.e., high
and low molecular weight proteins, were present in the urine.
DPPIV Inhibition Increases Renal Cortical
Expression of Megalin, Nephrin and
Podocin Expression in Rats with
Established HF
Given the anti-proteinuric effect of vildagliptin treatment, we
next tested the hypothesis that DPPIV inhibition could regulate
the expression of components of the apical endocytic machinery
in the renal proximal tubule (megalin and cubilin) (Willnow
et al., 1996; Leheste et al., 1999; Birn and Christensen, 2006)
and/or components of the glomerular filtration barrier, including
nephrin and podocin (Kestila et al., 1998; Tryggvason, 1999;
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FIGURE 6 | DPPIV inhibition by vildagliptin improves renal handling of sodium and water of HF rats. Sham and HF rats treated with vildagliptin (HF +
IDPPIV) or vehicle (HF) were individually placed into metabolic cages for 24-h urine collection for three consecutive days to evaluate (A) urinary flow and (B) urinary
Na+ excretion. (C)Water and food consumption were measured daily. (D) Sodium intake was calculated based on the sodium content of the rodent chow and on the
daily consumption of chow by each rat. (E) Water and (F) sodium balance. n = 11–17 rats/group. Values are means ± SEM. **p < 0.01 and ***p < 0.001 vs. Sham.
#p < 0.05, ##p < 0.01, ###p < 0.001 vs. HF.
Boute et al., 2000; Luimula et al., 2000; Agrawal et al., 2013).
As shown in Figure 9A, the protein expression of the endocytic
receptor megalin was significantly reduced in the cortex of HF
rats compared to sham rats (69 ± 6 vs. 100 ± 3%, p < 0.05).
Interestingly, vildagliptin treatment upregulatedmegalin to levels
higher than sham rats (142 ± 11 vs. 100 ± 3%, p < 0.01).
Conversely, the abundance of cubilin in the renal cortex was
similar among the three groups of rats (Figure 9B). Although
the podocyte main slit diaphragm proteins (Kestila et al., 1998;
Tryggvason, 1999; Boute et al., 2000; Luimula et al., 2000;
Agrawal et al., 2013), nephrin and podocin, were similar between
sham and vehicle-treated HF rats, they were upregulated by
DPPIV inhibition in the renal cortex of rats with established HF
(Figures 9C,D).
DISCUSSION
The heart and the kidney are very closely related. Cardiac
impairment can result in renal dysfunction, and worsening
of renal function is a strong predictor of long-term adverse
outcomes in patients with HF. In the present study, we
demonstrated that chronic treatment with the DPPIV inhibitor
vildagliptin exerts renoprotective and cardioprotective effects
in rats with established HF, reversing cardiac remodeling and
improving both LV systolic and diastolic function. Long-
term renoprotection conferred by DPPIV inhibition involves
improved renal handling of sodium and water which may have
ultimately led to relief of volume expansion and pulmonary
congestion in HF. Additionally, DPPIV inhibition significantly
reduces proteinuria in HF rats. The anti-proteinuric effects of
DPPIV inhibition were associated with upregulation of the apical
proximal tubule endocytic receptor megalin as well as of the
podocyte main slit diaphragm proteins nephrin and podocin.
We have recently reported (dos Santos et al., 2013) that
humans and rats with HF exhibit higher plasma levels of DPPIV
activity and abundance compared to their healthy counterparts.
Additionally, previous studies from our laboratory (dos Santos
et al., 2013) and others (Sauvé et al., 2010; Gomez et al., 2012;
Shigeta et al., 2012; Aoyama et al., 2016) have demonstrated
that genetic deletion or pharmacologic inhibition of DPPIV
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FIGURE 7 | Treatment with vildagliptin increases NHE3 phosphorylation at the PKA consensus site serine 552 in the renal cortex of HF rats. (A)
Representative immunoblotting of renal cortical proteins probed with a phosphospecific NHE3 mAb that recognizes NHE3 only when it is phosphorylated at serine
552 (PS552-NHE3), total NHE3 mAb or anti-actin. (B) Graphical representation of the relative PS552-NHE3 and (C) total NHE3 levels. The relative abundance of
PS552-NHE3 was quantitated by densitometry and expressed as a ratio of PS552-NHE3/total. The combined data from 4 experiments are represented. Values are
means ± SEM. *p < 0.05 and ***p < 0.001 vs. Sham. ###p < 0.001 vs. HF.
prevents the onset of HF after myocardial infarct/injury in
rodents and large animal models. However, to the best of our
knowledge, this is the first report that reveals that DPPIV
inhibition can exert not only preventive but also therapeutic
effects in HF by restoring myocardial structure and function.
Our results that vildagliptin ameliorated cardiorenal function
in rats with established HF contrast with those from Yin et al.
(2011). These authors did not observe any beneficial effect of
vildagliptin at a daily dose of 15 mg/kg/day once daily on either
preventing or reversing cardiac remodeling and dysfunction in
post-myocardial infarcted rats. One plausible explanation of this
discrepancy between our findings and theirs is the higher dose
(120 vs. 15 mg/kg/day) and higher frequency of administration
of vildagliptin we employed (twice daily vs. once daily dosing).
Indeed, we have noticed that although chronic treatment with
20 mg/kg/day vildagliptin inhibits plasma DPPIV activity, it fails
to inhibit the activity of the peptidase in the heart and in the
kidneys of HF rats. Moreover, at this low dose, vildagliptin is
unable to ameliorate cardiac and renal function and to reduce
pulmonary congestion in rats with established HF (unpublished
observations). In concert, these observations suggest that local
inhibition of DPPIV activity in the heart and possibly in the
kidney may have a pivotal role in mediating the therapeutic
effects of DPPIV inhibitors in rats with HF.
An intriguing finding of the present work is that
administration of vildagliptin, a competitive inhibitor of DPPIV
catalytic activity, not only inhibits the activity of DPPIV but
also reduces the protein and mRNA-expression of the peptidase
in the heart of HF rats. Similarly, Kanasaki et al. (2014) have
recently reported that administration of the DPPIV inhibitor
linagliptin reduces DPPIV activity and expression in the kidney
and endothelial cells of streptozotocin-induced diabetic mice.
Reduced DPPIV expression in these diabetic mice was associated
with an upregulation of components of the microRNA (miRNA)
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FIGURE 8 | DPPIV inhibition improves GFR and reduces proteinuria in HF rats. (A) The glomerular filtration rate (GFR) was estimated by the creatinine
clearance. (B) Urine protein to creatinine ratio. n = 11–17 rats/group. (C) Profile of urinary proteins excreted by sham and HF rats treated with vehicle (HF) or
vildagliptin (HF + IDPPV). The 24-h urine samples (volume equivalent to 25 µg of creatinine) were subjected to 10% SDS-PAGE. Following electrophoresis, the gels
were silver stained using the ProteoSilver Plus Kit (Sigma-Aldrich). (D) Graphic representation of the amount of intact albumin semiquantitatively evaluated by
densitometry. n = 6 rats/group. Values are means ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 vs. Sham. #p < 0.05, ##p < 0.01 vs. HF.
29 family. Interestingly, the miRNA 29 family has been shown to
be downregulated after myocardial infarction (van Rooij et al.,
2008; Melo et al., 2014), and this downregulation contributes to
cardiac fibrosis (van Rooij et al., 2008). However, it remains to be
established whether this post-transcriptional mechanism is also
involved in the upregulation of DPPIV activity/expression in the
heart of experimental models of HF.
The cardioprotective effects of DPPIV inhibition are often
attributed to increased bioavailability of GLP-1, BNP, and SDF-
1α that ameliorate cardiac performance and contractility, reduce
hypertrophy, fibrosis and apoptosis, and improve stem cell
mobilization and angiogenesis to the myocardium (Zaruba et al.,
2009; Shigeta et al., 2012; dos Santos et al., 2013; Hocher et al.,
2013). The present data suggest a role for the renoprotective
actions of vildagliptin in the outcomes of rats with established
HF. Indeed, it is undeniable that neurohumoral activation in
response to the low output in decompensated HF and the
consequent water and salt retention by the kidneys are important
factors that increase circulatory filling pressure and restore
cardiac ejection (Cadnapaphornchai et al., 2001; Chatterjee, 2005;
Brum et al., 2006). However, chronic and excessive volume
expansion with increased preload can lead to cardiac remodeling
and dilation, which has deleterious effects on cardiac function.
In fact, changes on renal function are not only a marker of HF
but may also be a pathogenic factor in causing the progression of
cardiac deterioration (Boerrigter et al., 2013). One may therefore
speculate that improvement of cardiac remodeling and function
in vildagliptin-treated HF rats may result, at least in part, from
restored renal function.
Derangements in several hormonal systems contribute to
sodium and water retention in HF. The results from our previous
(dos Santos et al., 2013) and present work suggest that restoration
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FIGURE 9 | The antiproteinuric effects of DPPIV inhibition are associated with upregulation of megalin, nephrin, and podocin expressions in the
kidneys of HF rats. Equal amounts of renal cortical proteins isolated from sham and HF rats treated with vildagliptin (HF + IDPPIV) or vehicle (HF) (10 µg for megalin
and cubilin, 30 µg for nephrin and podocin and 5 µg for actin) were subjected to SDS-PAGE, transferred to a PVDF membrane and incubated with primary antibodies
against (A) megalin (1:50,000), (B) cubilin (1:1000), (C) nephrin (1:11,000), or (D) podocin (1:11,000). Actin was used as an internal control. Values are means ± SEM.
*p < 0.05 and **p < 0.01 vs. Sham. #p < 0.05, ###p < 0.001 vs. HF.
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of the GLP-1/GLP-1R signaling activation in the renal cortex
may be implicated in the vildagliptin-mediated amelioration of
renal function in HF rats. The acute diuretic and natriuretic
actions of GLP-1 have been consistently demonstrated by a
variety of studies in rodents (Moreno et al., 2002; Crajoinas
et al., 2011; Rieg et al., 2012; Thomson et al., 2013; Farah et al.,
2016) and humans (Gutzwiller et al., 2004, 2006; Skov et al.,
2013). The effects of GLP-1 on sodium and water handling
in both rodents and humans is mediated, at least in part, by
inhibition of NHE3-mediated renal proximal tubule sodium
reabsorption via activation of the cAMP/PKA signaling pathway
(Crajoinas et al., 2011; Rieg et al., 2012; Thomson et al., 2013;
Farah et al., 2016). Accordingly, in the present work, we found
that vildagliptin administration in rats with established HF
elevated the concentration of circulating active GLP-1, and most
likely, the concentration of this incretin hormone in the renal
tubular fluid restores PKA activation to the levels of sham
rats. These events were associated with higher levels of renal
cortical NHE3 phosphorylation at the PKA consensus site serine
552, a surrogate for reduced NHE3 transport activity in the
proximal tubule (Crajoinas et al., 2010; Girardi and Di Sole,
2012). It is noteworthy that GLP-1 also exerts diuretic and
natriuretic effects in rodents through increments in both renal
blood flow and GFR (Jensen et al., 2015). Indeed, recent studies
have shown that GLP-1R is expressed in the afferent arterioles
and that stimulation of GLP-1R by specific agonists increases
renal blood flow (Thomson et al., 2013; Jensen et al., 2015).
Therefore, our finding that HF rats treated with vildagliptin
display higher GFR than vehicle-treated HF rats may also be due,
at least in part, to the activation of GLP-1/GLP-1R in the renal
vasculature.
DPPIV modulates multiple substrates other than GLP-1 that
exert natriuretic and/or renoprotective effects, such as BNP, SDF-
1α, substance P, among others (Makino et al., 2015). Thus, it
is important to emphasize that the beneficial effects of DPPIV
inhibition on sodium and water balance in HF shown herein
might, in part, occur via GLP-1 independent mechanisms. In
this context, Rieg and colleagues found that administration of
the DPPIV inhibitor alogliptin was capable of inducing diuresis
and natriuresis in GLP-1R knockout mice (Rieg et al., 2012).
Moreover, we have previously found that inhibition of the
catalytic activity of DPPIV inhibits NHE3 activity in the opossum
kidney clone P (OKP) proximal tubule cell line, and it is well
known that the proximal tubule does not synthesize GLP-1
(Girardi et al., 2008).
In addition to the effects on sodium and water homeostasis,
pharmacological administration of DPPIV inhibitors confers
renoprotection by reducing proteinuria and ameliorating renal
damage in experimental models of diabetic nephropathy (Liu
et al., 2012; Kanasaki et al., 2014; Eun Lee et al., 2016). The
anti-proteinuric effects of DPPIV inhibition have also been
observed in type 2 diabetes patients (Hattori, 2011; Groop
et al., 2013; Kawasaki et al., 2015; Nakamura et al., 2016). In
the present study, we found that HF rats display tubular and
glomerular proteinuria and that tubular proteinuria in these
animals was associated with reduced expression of the endocytic
receptor megalin. On the other hand, the origin of glomerular
proteinuria in these rats remains obscure. It is worth mentioning
that glomerular proteinuria has not often been associated with
lower expression of nephrin but instead with changes in the
levels of tyrosine phosphorylation of its cytoplasmic tail (Carney,
2016; New et al., 2016). Surprisingly, treatment with vildagliptin
upregulated megalin as well as the podocyte slit diaphragm
proteins nephrin and podocin in the kidneys of HF rats to
levels higher than sham. The molecular mechanisms by which
vildagliptin increases the abundance of megalin, nephrin and
podocin in the renal cortex of HF rats is yet to be established.
In summary, our findings demonstrated that the DPPIV
inhibitor vildagliptin exerts renoprotective effects and
ameliorates cardiorenal function in rats with established HF.
Moreover, our data suggest that DPPIV may constitute one of
the pathophysiological connections between the failing heart and
kidneys. Given the lack of pharmacological agents that directly
improve renal function in patients with HF, long-term studies
with DPPIV inhibitors are warranted to ascertain whether the
renoprotective effects of DPPIV inhibition ultimately translate
into improved clinical outcomes.
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